Arcellx, Inc. $ACLX Shares Bought by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its stake in Arcellx, Inc. (NASDAQ:ACLX) by 7.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,428 shares of the company’s stock after purchasing an additional 228 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Arcellx were worth $226,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ACLX. Vestal Point Capital LP grew its stake in shares of Arcellx by 402.7% in the 1st quarter. Vestal Point Capital LP now owns 2,387,720 shares of the company’s stock valued at $156,634,000 after purchasing an additional 1,912,720 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Arcellx by 135.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,665,138 shares of the company’s stock valued at $109,234,000 after purchasing an additional 959,216 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Arcellx by 19.7% in the 1st quarter. Vanguard Group Inc. now owns 3,985,156 shares of the company’s stock valued at $261,426,000 after purchasing an additional 655,064 shares during the last quarter. RA Capital Management L.P. grew its stake in shares of Arcellx by 8.9% in the 1st quarter. RA Capital Management L.P. now owns 3,036,527 shares of the company’s stock valued at $199,196,000 after purchasing an additional 249,200 shares during the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of Arcellx by 103.4% in the 1st quarter. Voya Investment Management LLC now owns 277,102 shares of the company’s stock valued at $18,178,000 after purchasing an additional 140,899 shares during the last quarter. 96.03% of the stock is currently owned by hedge funds and other institutional investors.

Arcellx Stock Performance

ACLX opened at $84.68 on Friday. The business’s fifty day moving average is $78.44 and its two-hundred day moving average is $69.75. The company has a market cap of $4.70 billion, a price-to-earnings ratio of -24.76 and a beta of 0.31. Arcellx, Inc. has a one year low of $47.86 and a one year high of $107.37.

Arcellx (NASDAQ:ACLX) last posted its earnings results on Thursday, August 7th. The company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The company had revenue of $7.55 million for the quarter, compared to the consensus estimate of $16.76 million. Arcellx had a negative return on equity of 43.04% and a negative net margin of 329.93%. On average, analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on ACLX shares. Scotiabank lifted their target price on Arcellx from $93.00 to $133.00 and gave the company a “sector outperform” rating in a research note on Thursday, July 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Arcellx in a research note on Friday. Cantor Fitzgerald restated a “neutral” rating and issued a $88.00 price target on shares of Arcellx in a research note on Thursday, October 9th. Finally, Stifel Nicolaus set a $129.00 price target on Arcellx and gave the company a “buy” rating in a research note on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $113.08.

Insider Buying and Selling

In other Arcellx news, insider Christopher Heery sold 21,034 shares of the business’s stock in a transaction on Tuesday, September 30th. The stock was sold at an average price of $81.28, for a total transaction of $1,709,643.52. Following the sale, the insider directly owned 624 shares in the company, valued at approximately $50,718.72. The trade was a 97.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 37,146 shares of company stock worth $3,000,136 in the last quarter. 8.35% of the stock is currently owned by insiders.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).